LONG MINI FUTURE WARRANT - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-06-10 pm EDT | ||
| 216.6 EUR | +0.84% |
|
| Current month | +7.94% | ||
| 1 month | +14.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 216.6 | +0.84% |
| 24-06-07 | 214.8 | +1.35% |
| 24-06-06 | 212 | +4.41% |
| 24-06-05 | 203 | -0.05% |
| 24-06-04 | 203.1 | +1.89% |
Real-time Euronext Paris
Last update June 10, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| C68XH | |
| ISIN | NL0014740920 |
| Date issued | 2020-04-21 |
| Strike | 181 kr |
| Maturity | Unlimited |
| Parity | 0.5 : 1 |
| Emission price | 10.77 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 217.3 € |
|---|---|
| Lowest since issue | 5.3 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.96%
- Stock Market
- Certificates
- C68XH Certificat
